Corporations are going to use IP law to profit from psychedelics. But creative strategies from other industries could help people push back against exclusionary ownership and keep drugs accessible.
The non-profit Freedom to Operate used research from chemists and crystallographers to argue in a legal filing that Compass’ form of synthetic psilocybin is not a new invention.
For-profit companies want psychedelics to be treated as medicine; others want them to just be legal. They'll have to learn to get along.
A recent application from CB Therapeutics on biosynthetic psilocybin is emblematic of the IP concerns around novelty and obviousness the psychedelic field will face.
The debate around psychedelic patents reflects a deeper question about how to create a business model that puts values before profits.
In a series of open letters and statements, investors have been debating how patents will shape the future—who will get to use psychedelics, and who will profit.
Compass Pathways, a Peter Thiel-backed psychedelic mental health company, has made patent application claims on aspects of psilocybin-assisted therapy as basic as using soft furniture and holding hands.
Don’t expect to pick up prescription shrooms at CVS, though.